Efficacy of 153Sm-EDTMP on Bone Pain Palliation in Metastatic Patients: Breast and Prostate Cancers

Mojtaba  Rokni; Mehrangiz  Amiri; Kourosh  Ebrahimnejad Gorji; Hoda  Talebian; Ali  Shabestani Monfared

doi:10.18502/fbt.v10i3.13161

Mojtaba Rokni Student Research Committee, Babol University of Medical Sciences, Babol, Iran
Mehrangiz Amiri Department of Nuclear Medicine, Babol University of Medical Sciences, Babol, Iran
Kourosh Ebrahimnejad Gorji Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran
Hoda Talebian Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran
Ali Shabestani Monfared Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

DOI: https://doi.org/10.18502/fbt.v10i3.13161

Keywords: Breast Cancer; Prostate Cancer; Bone Metastasis; 153 Samarium Ethylenediamine Tetra (Methylene Phosphonic Acid).

Abstract

Purpose: This study aimed to evaluate the effect of samarium-153-EDTMP (¹⁵³Sm-EDTMP) on pain relief bone metastases of Breast Cancer (BC) and Prostate Cancer (PC) patients.

Materials and Methods: Thirty patients aged 40-77 years (62.6±10.2 years) with intractable metastatic bone pain were included in the current study. A checklist of patient information and a standard questionnaire for the assessment of pain and quality of life were completed before and after four and eight week’s palliative treatment with 37 MBq/kg of ¹⁵³Sm-EDTMP. To analyse the data, parametric and non-parametric tests were used in SPSS software.

Results: Twelve females with BC (40%) and 18 males with PC (60%) were included. Four and eight weeks after palliative treatment of ¹⁵³Sm-EDTMP, the mean pain score reduction and quality of life were statistically increased compared to before the intervention (P-value < 0.05). Notably, the amount of pain reduction in the fourth week was more than in the eighth week; however, the quality of life was better in the eighth week, without significant variation (P-value <0.05). In addition, there was no statistically significant relationship between pain reduction and the type of primary diseases, BC, and PC (P-value >0.05).

Conclusion: The injection of ¹⁵³Sm-EDTMP had therapeutic efficacy for bone pain palliation in patients with diffuse bone metastases at the end of the 4th and 8th week post-infusion.